New approaches for identifying and testing potential new anti-asthma agents

Amelia Licari, Riccardo Castagnoli, Ilaria Brambilla, Alessia Marseglia, Maria Angela Tosca, Gian Luigi Marseglia, Giorgio Ciprandi

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment.

Original languageEnglish
Pages (from-to)51-63
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Asthma
Phenotype
Therapeutics
Biomarkers
Airway Remodeling
Expert Testimony
Patient Rights
Chronic Disease
Research Personnel
Pharmacology
Research
Pharmaceutical Preparations

Keywords

  • Airway Remodeling/drug effects
  • Animals
  • Anti-Asthmatic Agents/pharmacology
  • Asthma/diagnosis
  • Biomarkers/metabolism
  • Chronic Disease
  • Drug Design
  • Humans
  • Molecular Targeted Therapy
  • Phenotype

Cite this

New approaches for identifying and testing potential new anti-asthma agents. / Licari, Amelia; Castagnoli, Riccardo; Brambilla, Ilaria; Marseglia, Alessia; Tosca, Maria Angela; Marseglia, Gian Luigi; Ciprandi, Giorgio.

In: Expert Opinion on Drug Discovery, Vol. 13, No. 1, 01.2018, p. 51-63.

Research output: Contribution to journalReview article

Licari, Amelia ; Castagnoli, Riccardo ; Brambilla, Ilaria ; Marseglia, Alessia ; Tosca, Maria Angela ; Marseglia, Gian Luigi ; Ciprandi, Giorgio. / New approaches for identifying and testing potential new anti-asthma agents. In: Expert Opinion on Drug Discovery. 2018 ; Vol. 13, No. 1. pp. 51-63.
@article{01d99d09f83d46308ce71c1fb6f7be4c,
title = "New approaches for identifying and testing potential new anti-asthma agents",
abstract = "INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment.",
keywords = "Airway Remodeling/drug effects, Animals, Anti-Asthmatic Agents/pharmacology, Asthma/diagnosis, Biomarkers/metabolism, Chronic Disease, Drug Design, Humans, Molecular Targeted Therapy, Phenotype",
author = "Amelia Licari and Riccardo Castagnoli and Ilaria Brambilla and Alessia Marseglia and Tosca, {Maria Angela} and Marseglia, {Gian Luigi} and Giorgio Ciprandi",
year = "2018",
month = "1",
doi = "10.1080/17460441.2018.1396315",
language = "English",
volume = "13",
pages = "51--63",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - New approaches for identifying and testing potential new anti-asthma agents

AU - Licari, Amelia

AU - Castagnoli, Riccardo

AU - Brambilla, Ilaria

AU - Marseglia, Alessia

AU - Tosca, Maria Angela

AU - Marseglia, Gian Luigi

AU - Ciprandi, Giorgio

PY - 2018/1

Y1 - 2018/1

N2 - INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment.

AB - INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment.

KW - Airway Remodeling/drug effects

KW - Animals

KW - Anti-Asthmatic Agents/pharmacology

KW - Asthma/diagnosis

KW - Biomarkers/metabolism

KW - Chronic Disease

KW - Drug Design

KW - Humans

KW - Molecular Targeted Therapy

KW - Phenotype

U2 - 10.1080/17460441.2018.1396315

DO - 10.1080/17460441.2018.1396315

M3 - Review article

C2 - 29077521

VL - 13

SP - 51

EP - 63

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 1

ER -